Human Growth Hormone

Human Growth Hormone

• Home
• What is HGH?
• Search
• Syndicate
• More Health

See Also

Human Growth Hormone > Saizen > Geneva

Please select a HGH news story from the list below:

• Business Wire - Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
• PR Newswire Europe - FDA Approval of easypod(R): New Electronic Growth Hormone Injection Device.
• Business Wire - Serono and IVAX Announce Positive Outcome of Pharmacokinetic Trials with Oral Cladribine
• Business Wire - ZymoGenetics and Serono Initiate Clinical Trial with TACI-Ig
• Business Wire - Serono And IVAX To Develop Oral Therapy For Multiple Sclerosis
• Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva
• Business Wire - Serono Subscribes to Celera's Genomic Databases
• Business Wire - Palatin Enters Research Agreement With Serono to Generate Compounds Using Palatin's MIDAS Drug Design Technology
• Business Wire - Alkermes and Serono to Proceed With Development of Long-acting Formulation of Recombinant Human Follicle Stimulating Hormone - R-hFSH
• Business Wire - Alkermes Announces Completion of Patient Enrollment in Phase I Clinical Trial of Injectable Sustained Release Formulation of Serono Drug

Business Wire - Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

December 20, 2007 -- Flamel's Medusa([R]) technology designed to allow less frequent administration of therapeutic proteins and peptides LYON, France -- Flamel...

• Business Wire - Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

PR Newswire Europe - FDA Approval of easypod(R): New Electronic Growth Hormone Injection Device.

November 8, 2007 -- GENEVA, Switzerland, November 8 /PRNewswire/ -- - Innovative Device Designed for Simple Everyday Use by Patients and Caregivers Merck...

• PR Newswire Europe - FDA Approval of easypod(R): New Electronic Growth Hormone Injection Device.

Business Wire - Serono and IVAX Announce Positive Outcome of Pharmacokinetic Trials with Oral Cladribine

March 23, 2004 -- Business Editors/Health/Medical Writers GENEVA & MIAMI--(BUSINESS WIRE)--March 23, 2004 Cladribine Targeted to Become First Oral Therapy for...

• Business Wire - Serono and IVAX Announce Positive Outcome of Pharmacokinetic Trials with Oral Cladribine

Business Wire - ZymoGenetics and Serono Initiate Clinical Trial with TACI-Ig

September 29, 2003 -- Business Editors/Health/Medical Writers SEATTLE & GENEVA--(BUSINESS WIRE)--Sept. 29, 2003 Inhibitor of B-cell Activation Provides Novel...

• Business Wire - ZymoGenetics and Serono Initiate Clinical Trial with TACI-Ig

Business Wire - Serono And IVAX To Develop Oral Therapy For Multiple Sclerosis

October 30, 2002 -- Business Editors/Health & Medical Writers GENEVA, Switzerland & MIAMI--(BUSINESS WIRE)--Oct. 30, 2002 Serono S.A. (virt-x: SEO)...

• Business Wire - Serono And IVAX To Develop Oral Therapy For Multiple Sclerosis

Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva

August 8, 2002 -- Business Editors/Health & Medical Writers GENEVA & SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 7, 2002 Serono S.A. (virt-x:...

• Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva

Business Wire - Serono Subscribes to Celera's Genomic Databases

December 20, 2001 -- Business Editors/Medical & Health Writers BIOWIRE2K ROCKVILLE, MD, and GENEVA, Switzerland--(BW HealthWire)--Dec. 20, 2001 Celera Genomics...

• Business Wire - Serono Subscribes to Celera's Genomic Databases

Business Wire - Palatin Enters Research Agreement With Serono to Generate Compounds Using Palatin's MIDAS Drug Design Technology

October 1, 2001 -- Business Editors & Health/Medical Writers PRINCETON, N.J.--(BW HealthWire)--Oct. 1, 2001 Palatin Technologies, Inc. (AMEX: PTN) announced today...

• Business Wire - Palatin Enters Research Agreement With Serono to Generate Compounds Using Palatin's MIDAS Drug Design Technology

Business Wire - Alkermes and Serono to Proceed With Development of Long-acting Formulation of Recombinant Human Follicle Stimulating Hormone - R-hFSH

May 16, 2001 -- Business Editors & Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass. and GENEVA, Switzerland--(BW HealthWire)--May 16, 2001 Alkermes, Inc.,...

• Business Wire - Alkermes and Serono to Proceed With Development of Long-acting Formulation of Recombinant Human Follicle Stimulating Hormone - R-hFSH

Business Wire - Alkermes Announces Completion of Patient Enrollment in Phase I Clinical Trial of Injectable Sustained Release Formulation of Serono Drug

November 29, 2000 -- Business Editors/Health & Medical Writers CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 29, 2000 Alkermes, Inc. (NASDAQ:ALKS) announced today that...

• Business Wire - Alkermes Announces Completion of Patient Enrollment in Phase I Clinical Trial of Injectable Sustained Release Formulation of Serono Drug

Cities

geneva lyon medical writers cambridge medical writers princeton miami south san francisco

Province/States

california massachusetts new jersey

Countries

france switzerland